Sagenit efficiency in the treatment of vulvovaginal symptoms of aging


  • О. В. Грищенко Kharkiv Academy of Postgraduate Education, Ukraine
  • И. В. Лахно Kharkiv Medical Academy of Postgraduate Education, Ukraine



menopause, vulvovaginal atrophy, SERM effect, Sagenit


It was performed the investigation of the vaginal rehabilitation efficiency with the application of Sagenit and Gexicon in menopausal women with the symptoms of vulvovaginal atrophy. Clinical symptoms of the surveyed ladies were due to vaginal wall impaired blood supply and associated inflammation. It was reduced the index of vaginal health. Combined administration of Sagenit and Gexicon has led to the significant clinical dynamics of treatment according to the index of vaginal health that was characterized the improvement of colpotrophic processes and vaginal microecology. It was not registered endometrial growth by ultrasonography during the usage of Sagenit that has confirmed SERM effect. The proposed method of the vaginal rehabilitation is safe and highly effective in the aged group of patients. It allows counting on its widespread adoption in the management of women with the intermediate menopausal disorders.

Author Biographies

О. В. Грищенко, Kharkiv Academy of Postgraduate Education

MD, Professor, Dean of Faculty of Pediatrics

И. В. Лахно, Kharkiv Medical Academy of Postgraduate Education

PhD, assistant professor

Obstetrics, Gynecology and Perinatology Department


  1. Bachmann G, Lobo RA, Gut R et al. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial // Obstet Gynecol. – 2008. – Vol. 111, No 1. – P.67-76.
  2. Chollet AJ Update on alternative therapies for vulvovaginal atrophy // Patient Prefer Adherence. – 2011. – Vol. 5. – P. 533-536.
  3. Cleve A, Fritzemeier KH, Haendler B et al. Pharmacology and clinical use of sex steroid hormone receptor modulators // Handb Exp Pharmacol. – 2012. – Vol. 214. – P. 543-587.
  4. Cuzick J, Sestak I, Bonanni B et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data // Lancet. – 2013. – Vol. 381. – P. 1827-1834.
  5. Mac Bride BM, Rhodes JD, Shuster TL Vulvovaginal Atrophy // Mayo Clin Proc. – 2010. – Vol. 85, No 1. – P. 87-94.
  6. Simon JA Vulvovaginal atrophy: new and upcoming approaches [editorial] // Menopause. – 2009. – Vol. 16, No 1. – P. 5-7.
  7. Wend K, Wend P, Krum SA Tissue-Specific Effects of Loss of Estrogen during Menopause and Aging // Front Endocrinol (Lausanne). – 2012. – Vol. 3. – P. 19-25.
  8. Neumark AI, Shelkovnikova NV The efficacy of the Sagenit in the treatment of women with urogenital disorders during the peri- and postmenopausal // Women’s Health. – 2013. – № 3 (79). – P. 160-163.
  9. Smetnik VP Sagenit efficiency at menopause syndrome // Obstetrics and Gynecology. – 2010. – № 4. – P. 94-96.



How to Cite

Грищенко, О. В., & Лахно, И. В. (2013). Sagenit efficiency in the treatment of vulvovaginal symptoms of aging. REPRODUCTIVE ENDOCRINOLOGY, (13), 70–73.



Management of menopause